ArticleBlood advances2025
BRCA1/2 impact on the development of implant-associated lymphoma in women with breast cancer and textured implants.
Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- BRCA Mutation Carriers and Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Accumulating Evidence, Proposed Mechanism, and Implications for Reconstructive Planning and Follow-Up.Annals of surgical oncology · 2026Review
- Technique-Driven and Patient-Specific Variations in Complications of Mastectomy with Immediate Breast Reconstruction: An Evidence-Based Review.Journal of clinical medicine · 2026Review
- Incidence of lymphomas in a nationwide prospective cohort study of breast-implanted women.Breast (Edinburgh, Scotland) · 2026Article
- Beyond the Surface: Deciphering the Role of Genetic Susceptibility in BIA-ALCL Pathogenesis.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
abstractBreast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a type of T-cell lymphoma arising near textured breast implants. In a Dutch population, a higher prevalence of BRCA1/2 was found in BIA-ALCL. We analyzed the risk of BIA-ALCL occurrence related to BRCA in a large population of women with implants followed after breast cancer (BC) mastectomy. We compared the prevalence of BRCA1/2 between women from a large cohort of patients with BC who did and did not develop BIA-ALCL after reconstruction with textured implants. Hazard ratios (HRs) of developing BIA-ALCL were estimated using Cox regression. We also conducted a case-control study. Of 520 patients with BC tested for BRCA, the age-adjusted rate of developing BIA-ALCL for women with BRCA was 16 times the rate of BIA-ALCL among women without BRCA (95% confidence interval [CI], 3.6-76.1; P < .0003). Carrying bilateral implants (HR, 3.9; 95% CI, 0.4-32.7), chemotherapy (HR, 0.95; 95% CI, 0.2-4.2), and radiotherapy (HR, 0.37; 95% CI, 0.04-3.1) were not associated with BIA-ALCL. We also conducted a case-control study with 13 BIA-ALCL patients matched 1:3 with 39 controls. We used a complete enumeration of Bernoulli probability to rule out a nonassociation of BRCA with BIA-ALCL (P = .0002). In this study, we defined the role of BRCA1/2 mutations as a risk factor in developing BIA-ALCL in patients with BC. These results will help women undergoing breast reconstruction or with textured implants in place.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.